You are here: Industry Insights > Biogen

News List

Former FDA adviser calls for wider probe into Biogen Alzheimer’s drug approval expresspharma
July 22, 2021
A federal probe of the US Food and Drug Administration’s approval of a controversial new Alzheimer’s disease drug should look into why that decision was made without clear evidence of patient benefit, a former adviser to the agency said 20th.
Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications prnewswire
July 22, 2021
Mirimus, Inc., today announced a strategic collaboration with Biogen Inc. (NASDAQ: BIIB) focused on the development of RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications.
Eisai, Biogen’s Lecanemab Gets Breakthrough Designation in AD contractpharma
July 21, 2021
Eisai Co., Ltd. and Biogen’s lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer's disease (AD), was granted Breakthrough Therapy designation from the FDA.
Collaboration between AbbVie, Biogen and Pfizer creates world's largest browsable resource linking rare protein-coding genetic variants to human health and disease worldpharmanews
July 16, 2021
The access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie, Biogen Inc. and Pfizer.
Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis drugs
July 16, 2021
Biogen Inc. (Nasdaq: BIIB) and InnoCare Pharma Limited (HKEX: 09969) today announced that they have entered into a license and collaboration agreement for orelabrutinib, an oral small molecule Bruton’s tyrosine kinase inhibitor (BTKi)
Two Major Health Systems Will Not Administer Controversial Aduhelm drugs
July 16, 2021
Two major U.S. health systems say they will not administer Aduhelm, the controversial new drug for treating Alzheimer disease.
Biogen pays $125 million upfront for rights to InnoCare's orelabrutinib in MS deal firstwordpharma
July 13, 2021
Biogen has agreed to pay InnoCare Pharma $125 million upfront for exclusive rights to the oral BTK inhibitor orelabrutinib for the potential treatment of multiple sclerosis (MS) worldwide and certain autoimmune diseases outside of China.
Big pharma collaborates on free resource linking genetic variants to human disease europeanpharmaceuticalreview
July 12, 2021
The collaborative work has produced the largest browsable resource linking rare protein-coding genetic variants to human health and disease that will accelerate targeted drug development.
Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease firstwordpharma
July 09, 2021
Today, access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. (Nasdaq: BIIB) a
Tipping the scales - Aduhelm’s hefty price under the spotlight cphi-online
July 07, 2021
Biogen’s Alzheimer’s drug Aduhelm has recently secured FDA approval to much fanfare.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page